You just read:

Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options

News provided by

Aspyrian Therapeutics Inc.

Apr 27, 2017, 20:00 ET